TP53 R248Q peptide–major histocompatibility complex (MHC) complex (TP53 R248Q pMHC complex)

The TP53 R248Q peptide–MHC complex is a molecular complex formed when a peptide containing the R248Q mutation from the TP53 gene (encoding mutant p53 protein) is presented on the surface of tumor cells by a specific MHC class I or class II molecule. This mutation is among the most frequent TP53 hotspot mutations in human cancers and results in loss of normal p53 tumor suppressor activity, with gain-of-function oncogenic properties[3][4]. The mutant peptide can generate a neoantigen recognized by the immune system as non-self. Such neoantigen–MHC complexes are being investigated as highly specific immunotherapy targets, enabling T cell–mediated attack on only the tumor cells harboring the mutation. Therapies include TCR-mimic antibodies, T cell receptor (TCR)–engineered T cell therapies, and peptide vaccines. Selection of patients requires confirmation of both the R248Q mutation and the appropriate HLA/MHC allele. Targeting the TP53 R248Q peptide–MHC complex represents a cutting-edge approach to personalized cancer immunotherapy, although clinical and translational work is ongoing and no therapies are yet approved for this specific complex[2][3][4][5]. If further detail is required about the parent molecule (mutant p53 R248Q), see supporting mechanisms in mutant p53 gain-of-function, immune evasion, and cancer roles as cited[2][3][4].

Other names

p53 R248Q neoantigen–MHC complexTP53 mutant R248Q peptide–MHC complexmutant p53 R248Q–peptide–MHC

Presentation of the mutant TP53 R248Q–derived peptide by MHC molecules on tumor cells enables T cell recognition and killing of tumor cells by adoptive cell therapy or vaccines Stimulates cytotoxic T lymphocyte (CTL)–mediated anti-tumor immunity